The presentation marks a pivotal update for the Holon-based biotech company, which centers its pipeline on AI-driven target discovery. Dr. Yeku, an expert in gynecologic oncology, is expected to provide insights into the trial's methodology as the company targets a Q1 2027 window for interim median progression-free survival data. COM701 represents a potential first-in-class treatment, currently moving through clinical evaluation to address the immunosuppressive microenvironment of gynecologic cancers.
Compugen to Host Virtual KOL Event on COM701 Ovarian Cancer Trial
Compugen will hold a virtual event on October 5, 2026, to discuss the clinical progress of its anti-PVRIG antibody, COM701. The session features Dr. Oladapo Yeku of Harvard Medical School, who will outline the design of the ongoing MAIA-ovarian adaptive platform trial for relapsed platinum-sensitive ovarian cancer patients.
Beyond the clinical update, Compugen’s research team will demonstrate enhancements to Unigen™, their proprietary computational platform. This technology serves as the backbone for the company's broader immuno-oncology pipeline, which currently includes collaborations with AstraZeneca and Gilead. Following the technical review of the MAIA-ovarian study and platform advancements, management will host a live question-and-answer session.
Comments (0)
No comments yet. Be the first!